We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.60 | -0.53% | 112.00 | 923,117 | 16:35:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 112.00 | 113.00 | 112.20 | 112.00 | 112.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 30.75M | 3.79M | 0.0059 | 190.17 | 722.13M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:17 | UT | 25,583 | 112.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/10/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 03/10/2024 | 11:48 | ALNC |  Syncona makes further investment in Resolution Therapeutics |
| 03/10/2024 | 07:00 | UK RNS | Syncona Limited Resolution Series B and new Chair appointment |
| 03/10/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 02/10/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 01/10/2024 | 14:17 | UK RNS | Syncona Limited Total Voting Rights |
| 01/10/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 30/9/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 26/9/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 25/9/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
Syncona (SYNC) Share Charts1 Year Syncona Chart |
|
1 Month Syncona Chart |
Intraday Syncona Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/9/2024 | 12:36 | Wellcome to Syncona | 688 |
| 02/5/2020 | 23:59 | Synchronica - Major management change heralds new strategy | 2 |
| 28/1/2017 | 02:52 | Welcome to Syncona | 2 |
| 20/12/2016 | 15:28 | Synchronica - Mobile Technology - 2012 | 4,755 |
| 08/3/2012 | 00:18 | Synchronica SYNC - Mobile Phone Technology - 2011 | 3,347 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-10-04 15:35:17 | 112.00 | 25,583 | 28,652.96 | UT |
| 2024-10-04 15:15:37 | 112.88 | 7 | 7.90 | O |
| 2024-10-04 14:48:58 | 112.63 | 7,391 | 8,324.62 | O |
| 2024-10-04 14:31:19 | 112.35 | 15,000 | 16,852.50 | O |
| 2024-10-04 14:24:22 | 112.70 | 3,362 | 3,789.08 | O |
| Top Posts |
|---|
Posted at 04/10/2024 09:20 by Syncona Daily Update Syncona Limited is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 112.60p.Syncona currently has 641,327,660 shares in issue. The market capitalisation of Syncona is £719,569,635. Syncona has a price to earnings ratio (PE ratio) of 190.17. This morning SYNC shares opened at 112p |
Posted at 26/9/2024 12:36 by cousinit It's a difficult one. Who knows where the share price may have been now without them?The relatively unloved sector, NAV retreating where there has not been a materially positive move forward for some time now and the likely Witan overhang all cast a shadow. I guess you've got to take the view (if you're holding on!) that they will to get their mojo back at some point and that a reduced share count which was executed at prices below 130p made a worthwhile NAV accretion. Appreciate that the market doesn't believe the NAV, but CRS was buying stock back around 80p late last year with a then NAV just over 100p. NAV now north of 170p. |
Posted at 05/6/2024 09:53 by the shuffle man Trading at a huge discount to NAV even if you take into account the fall in Autolus shares since the last NAV valuation. All recent news from portfolio companies seems to be positive and the share price has bounced from these levels in the past so i have initiated a position. |
Posted at 21/5/2024 12:59 by ferrox5 SYNC bought 140K out of 350K traded |
Posted at 17/5/2024 13:10 by spectoacc Needs to hold down here really, otherwise it's all-time lows and then "who knows".But I do like a cheap share, particularly one ADVFN'ers seem to have gone quiet on. SYNC still got lots of cash, and Autolus, and most else is in for very little. But needs another sentiment turn on AUTL really. |
Posted at 17/5/2024 08:23 by spectoacc Autolus seems unable to keep its pants up for long. But SYNC still seems cheap to me, even if sometimes seems the only thing supporting it is the perma-buy back.Edit - bought back in today. My buys having zero effect on the price, so a good chance I'll be averaging lower, but cheap is cheap. |
Posted at 29/9/2023 10:10 by the shuffle man Share buy back seems to have stopped the drop for now. |
Posted at 21/9/2023 12:09 by salpara111 I made a small amount of money out of Sync several years ago.Just having another look again given the bombed out share price All of these sort of businesses have been hard hit by the rise in interest rates producing a double whammy of increased funding costs for portfolio companies and less opportunity to get an ipo away. Having said that a point is reached when sentiment is too negative and I think we are nearing that point, having said that, as previous posters have said, the business in now under serious pressure to produce some positive news flow which goes beyond just "we have made good progress with clinical trials" |
Posted at 18/9/2023 09:53 by spectoacc EPIC currently describes the share price :( |
Posted at 16/6/2022 16:06 by rambutan2 Finals out, all in all, quite good:The second half of CY2021 was marked by significant volatility across equity markets globally. This uncertainty has carried on into 2022, compounded by concerns around inflation, interest rates and Russia's invasion of Ukraine and the ongoing humanitarian crisis. This has impacted investor sentiment towards risk assets. We have seen a macro rotation away from growth stocks, impacting both valuations and financings of biotech companies, especially smaller, earlier stage companies. As market volatility has increased, the Syncona team continues to carefully review the requirements of each of our portfolio companies and our capital pool to ensure that our Company is well positioned to navigate continuing challenging markets. Our balance sheet provides us with a strategic advantage, and the team's expertise and rigorous approach to risk management means we continue to take a disciplined approach to capital allocation across a well-funded portfolio and exciting pipeline. Syncona ended the year with net assets of GBP1,309.8 million or 194.4p per share, a 0.3 per cent return in the year (31 March 2021: net assets of GBP1,300.3 million, NAV per share of 193.9p, 4.4 per cent return), despite the wider market backdrop for life science companies, which saw the NASDAQ Biotechnology Index decline 12 per cent during the period. The significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in share prices of our three listed companies, Autolus, Freeline and Achilles. We recognise that the performance of these listed companies has been disappointing for our shareholders. Our team have worked closely with portfolio company management teams to support them as they continue to execute their development plans. Similarly, the challenging market conditions have also impacted Syncona's share price performance in the financial year, which has been disappointing. Whilst the market environment for early stage biotech companies continues to be challenging, our listed companies are funded to deliver clinical data which represent key milestones for their businesses, and we believe Syncona is well positioned to deliver growth over the long term. |
Posted at 14/11/2021 16:12 by sev22 The Syncona Investment Trust, a member of Interactive Investor’s ACE 40 rated list of ethical investments, has reported its latest half-yearly results (11th November 2021):Syncona Ord (SYNC) investment trust, which invests in life science companies, reported a decline in net asset value of 11.4% for the first six months of its financial year – from the end of March to the end of September. Over this period, the trust reported that its net assets sat at £1.15 billion, down from £1.3 billion at the end of March 2021. Figures from FE Analytics show that over this period its share price total return was a loss of 33.6%, suffering from its high premium notably declining. The decline, the report notes, was driven predominantly by the decline in the share price of two of the trust’s listed holdings, Freeline Therapeutics Holdings ADR FRLN and Achilles Therapeutics ADR ACHL. Freeline’s poor performance is put down to “operational challenges” owing to the Covid-19 pandemic. Syncona says these concerns have now been addressed. Achilles’ share price decline was driven by “market sentiment towards cell and gene therapies”. Syncona says that it believes the business is performing well and in line with expectations. The trust’s strategy is to establish, build and fund companies to turn exceptional science into a dynamic portfolio of global leaders in life sciences. The aim is for the companies to deliver their product to market. The trust has a long-term target of owning between 15 and 20 companies. It currently has 10. Martin Murphy, chief executive of Syncona Investment Management Limited, said: “While we are disappointed by the decline in NAV during the period, we are continuing to build a diverse portfolio across the development cycle and therapeutic areas and remain confident in our companies' potential. The substantial capital that a number of our companies have accessed so far this year validate the significant opportunity ahead for them.” The trust also said that it planned to deploy another £100 million to £175 million into both existing companies and new opportunities this year. Murphy said: “With clinical data the key driver of value and risk for Syncona, we believe our companies are well positioned and on track to further validate our model and strategy in the next 12 months with the potential for a rich seam of data.” The trust is a member of Interactive Investor’s ACE 40 rated list of ethical investments. It was placed under formal review in the summer due to the volatility of its share price, but it kept its place on the list. Dzmitry Lipski, head of funds research at Interactive Investor, notes: “We remain positive on the trust outlook and see it as a strong choice for adventurous investors prepared to tolerate high volatility in the short term, but potentially reap rewards over the longer term. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
